Suberoylanilide hydroxamic acid enhances the radiosensitivity of lung cancer cells through acetylated wild-type and mutant p53-dependent modulation of mitochondrial apoptosis

J Int Med Res. 2021 Feb;49(2):300060520981545. doi: 10.1177/0300060520981545.

Abstract

Objective: Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, has shown potential as a candidate radiosensitizer for many types of cancers. This study aimed to explore the radiosensitization mechanism of SAHA in lung cancer cells.

Methods: Mutations in p53 were generated by site-directed mutagenesis using polymerase chain reaction. Transfection was performed to generate H1299 cells carrying wild-type or mutant p53. The radiosensitizing enhancement ratio was determined by clonogenic assays. Mitochondrial apoptosis was detected using JC-1 staining and flow cytometry analysis.

Results: Our results showed that SAHA induced radiosensitization in H1299 cells expressing wild-type p53, p53R175H or p53P223L, but this enhanced clonogenic cell death was not observed in parental H1299 (p53-null) cells or H1299 cells expressing p53 with K120R, A161T and V274R mutations. In SAHA-sensitized cells, mitochondrial apoptosis was induced following exposure to irradiation. Additionally, we observed that a secondary mutation at K120 (K120R) could eliminate p53-mediated radiosensitization and mitochondrial apoptosis.

Conclusions: The results of this study suggest that wild-type and specific mutant forms of p53 mediate SAHA-induced radiosensitization by regulating mitochondrial apoptosis, and the stabilization of K120 acetylation by SAHA is the molecular basis contributing to radiosensitization in lung cancer cells.

Keywords: Non-small cell lung cancer; acetylation; apoptosis; p53; radiosensitization; suberoylanilide hydroxamic acid.

MeSH terms

  • Apoptosis
  • Cell Line, Tumor
  • Histone Deacetylase Inhibitors / pharmacology
  • Humans
  • Hydroxamic Acids / pharmacology
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Radiation Tolerance
  • Tumor Suppressor Protein p53* / genetics
  • Vorinostat / pharmacology

Substances

  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids
  • TP53 protein, human
  • Tumor Suppressor Protein p53
  • Vorinostat